From the Announcements Highlights : Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance Imaging (MRI). Further in Paragraph 5 : The confirmation by the panel of the Company’s assessment that cancer detection can be achieved when using the MagSense® imaging agent with MRI has significant implications for the Company. Refer Pge 2 Paragraph 1 : “We will continue to refine our proprietary relaxometry technology but can now confidently shift our resources to developing our nanoparticles for use with MRI, a ubiquitous imaging modality used in hospitals and radiology clinics throughout the world. We believe this will be more attractive for strategic partners and more likely for us to achieve commercial success sooner.” Since all MagSense® targeted imaging agents use the same underlying magnetic nanoparticle technology, the Company now plans to prioritize the development of its MagSense® nanoparticle technology for use with mainstream clinical MRI scanners. (Later reference : there are 30,000 clinical grade MRI scanners globally)
IMO this good news announcement is the start of an SP turnaround as the market becomes aware of our potential. Further patient data will continue to build our support as it becomes available. Our commercialisation strategy is being revealed and Siemens involvement may be the next good news release.
IBX Price at posting:
2.9¢ Sentiment: Buy Disclosure: Held
